Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases

Anti‐angiogenic therapies using biological molecules that neutralize vascular endothelial growth factor‐A (VEGF‐A) have revolutionized treatment of retinal vascular diseases including age‐related macular degeneration (AMD). This study reports preclinical assessment of a strategy to enhance anti‐VEGF...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:EMBO Mol Med
Main Authors: Regula, Jörg T, Lundh von Leithner, Peter, Foxton, Richard, Barathi, Veluchamy A, Cheung, Chui Ming Gemmy, Bo Tun, Sai Bo, Wey, Yeo Sia, Iwata, Daiju, Dostalek, Miroslav, Moelleken, Jörg, Stubenrauch, Kay G, Nogoceke, Everson, Widmer, Gabriella, Strassburger, Pamela, Koss, Michael J, Klein, Christian, Shima, David T, Hartmann, Guido
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2016
Assuntos:
Research Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5090659/
https://ncbi.nlm.nih.gov/pubmed/27742718
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15252/emmm.201505889
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados